Major headway in depression study: 293 new genetic variants found
HQ Team January 20, 2025: Research has unveiled 293 new gene variants linked to major depressive disorder (MDD), significantly enhancing our understanding of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team January 20, 2025: Research has unveiled 293 new gene variants linked to major depressive disorder (MDD), significantly enhancing our understanding of.
HQ Team January 19, 2025: A study led by researchers from the Broad Institute, Harvard Medical School, and McLean Hospital has shed light.
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
HQ Team January 17, 2025: The commonly prescribed sleep medications, particularly zolpidem, known by its brand name Ambien, may disrupt the brain’s natural.
HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of.
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active.
Obesity, as defined by the standard body mass index, is erroneous, and the condition should be split into two — pre-clinical and clinical,.
At least eight people have died in Tanzania of suspected Marburg Virus Disease (MVD) and the regional risk is “high,” according to a.
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.